HF
ALNY icon

Hoxton Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hoxton Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,140
Closed -$138K – 340
2013
Q4 		$138K Buy
+2,140
New +$128K 0.06% 108

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hoxton Financial's ALNY Position: Q1 2014 in Review

Hoxton Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2014, closing a stake of 2,140 shares — an estimated $138K sold.

Hoxton Financial first reported a position in ALNY in Q4 2013 and held it in 1 quarter. The position peaked at $138K in Q4 2013. 198 funds tracked by Wall St. Rank hold ALNY as of Q1 2014.

  • Hoxton Financial reported no remaining Alnylam Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Hoxton Financial sold 2,140 Alnylam Pharmaceuticals shares in Q1 2014, an estimated $138K.
  • Hoxton Financial first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Hoxton Financial's Alnylam Pharmaceuticals position peaked at $138K in Q4 2013.
  • 198 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2014.

Based on Hoxton Financial's 13F filing for Q1 2014, filed 25 Apr 2014.